The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro

British Journal of Cancer

Volumn 89, Issue 2, 2003, Pages 357-362

  Abou El Hassan, M A I ^a   Verheul, H M W ^a   Jorna, A S ^a   Schalkwijk, C ^a   Van Bezu, J ^a   Van Der Vijgh, W J F ^a   Bast, A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Doxorubicin; HUVECs; MonoHER; MTT; Neutrophil adhesion

Indexed keywords

CELL ADHESION MOLECULE; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MONOHYDROXYETHYLRUTOSIDE; RUTOSIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CARDIOTOXICITY; CELL ADHESION; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HEART PROTECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MYOCARDITIS; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOTHELIUM, VASCULAR; HYDROXYETHYLRUTOSIDE; INFLAMMATION; NEUTROPHILS; UMBILICAL CORD;

EID: 0042622194     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601022     Document Type: Article

References (28)

1. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR (1980) Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 2: 487-515
2. Britten M, Schachinger V (1998) The role of endothelial function for ischemic manifestations of coronary atherosclerosis. Herz 23(2): 97-105
3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7): 1878-1886
4. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosil M, Osborn L, Chi-Rosso G, Newman B, Lobo R, Bosso M (1990) Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 76: 965-970
5. Clark CJ, Boswell F, Greer IA, Lyall F (1997) Treatment of endothelial cells with serum from women with preeclampsia: Effect on neutrophil adhesion. J Soc Gynecol Invest 4: 27-33
6. Decorti G, Candussio L, Klugmann FB, Strohmayer A, Mucci MP, Mosco A, Baldini L (1997) Adriamycin-induced histamine release from heart tissue in vitro. Cancer Chemother Pharmacol 40: 363-366
7. Decorti G, Klugmann FB, Candussio L, Furlani A, Scarcia V, Baldini L (1989) Uptake of adriamycin by rat and mouse mast cells and correlation with histamine release. Cancer Res 49: 1921-1926
8. Duffy SJ, Castle SF, Harper RW, Meredith IT (1999) Contribution of vasodialator prostanoids and nitric oxide to resting flow, metabolic vasodialation and flow-mediated dialation in human coronary circulation. Circulation 100: 1951-1957
9. Fujihira S, Yamamoto T, Matsumoto M, Yoshizawa K, Oishi Y, Fujii T, Noguchi H, Mori H (1993) The high incidence of atrial thrombosis in mice given doxorubicin. Toxicol Pathol 21(4): 362-368
10. Gerritsen ME, Carley WW, Ranges GE, Shen C, Phan SA, Ligon GF, Perry C (1995) Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol 147: 278-292
11. Goeptar AR, Groot EJ, Scheerens H, Commandeur JNM, Vermeulen NPE (1994) Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res 54: 2411-2418
12. Haenen GRMM, Jansen FP, Bast A (1993) The antioxidant properties of five O-(b-hydroxyethyl)-rutosides of the flavonoid mixture Venoruton. Phlebology(Suppl 1): 10-17
13. Havsteen B (1983) Flavonoids, a class of natural products of pharmacological potency. Biochem Pharmacol 32: 1141-1148
14. Hecker JF (1990) Survival of intravenous chemotherapy infusion sites. Br J Cancer 62(4): 660-662
15. Klohs WD, Hamby JM (1999) Antiangiogenic agents. Curr Opin Biotechnol 10(6): 544-549
16. Maciag T, Cerundolo J, Ilsely S, Kelley PR, Forand R (1979) An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci 76(11): 5674-5678
17. McLoon LK, Wirtschafter J (1997) Local injections of corticotropin releasing factor reduce doxorubicin-induced acute inflammation in the eyelid. Invest Ophthalmol Vis Sci 38(5): 834-841
18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
19. Mross K, Mayer U, Hamm K, Burk K, Hossfeld DK (1990) Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. Eur J Clin Pharmacol 39: 507-513
20. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypothesis. EASEB J 4: 3076-3086
21. Schaefer U, Schneider D, Rixen D, Neugebauer E (1998) Neutrophil adhesion to histamine stimulated cultured endothelial cells is primarily mediated via activation of phospholipase C and nitric oxide synthase isozymes. Inflamm Res 47: 256-264
22. Schwartz CL, Hobbie WL, Treusdel S, Constine LC, Clark EB (1993) Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 11: 1906-1910
23. Takacs IE, Matkovics B, Varga SI, Homolay P, Feher G, Seres T (1992) Study of the myocardial antioxidant defense in various species. Pharmacol Res 25: 177-178
24. Van Acker FA, Van Acker SA, Kramer K, Haenen GR, Bast A, Van der Vijgh WJF (2000) 7-monohydoxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6(4): 1337-1341
25. Van Acker SABE, Towart R, Husken BCP, De Jong J, Van der Vijgh WJF, Bast A (1993) The protective effect of Venoruton and its main constituents on acute doxorubicin-induced cardiotoxicity. Phlebology (Suppl. 1): 31-32
26. Van Acker SA, Boven E, Kuiper K, Van den Berg D, Grimbergen JA, Kramer K, Bast A, Van der Vijgh WJF (1997) Monohydoxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin. Cancer Res. 3: 1747-1754
27. Van der Vijgh WJF, Maessen PA, Pinedo HM (1990) Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother. Pharmacol 26: 9-12
28. Verheul HMW, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MFBG, Pinedo HM (2000) Vascular endothelial growth factor stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221